Funding for this research was provided by:
Health Technology Assessment Programme (16/145/01)
Cure Parkinson’s Trust (3013387)
Received: 28 October 2022
Accepted: 25 November 2022
First Online: 12 December 2022
: The study will be undertaken in compliance with the Helsinki Declaration. Ethical approval was granted by the London – Riverside Research Ethics Committee REC number 19/LO/0288. The protocol, informed consent forms and participant-facing material was submitted to the Research Ethics Committee (REC) and Health Research Authority (HRA). Any subsequent amendments will be submitted for further approval. Before initiation of the trial at each clinical site, the same documents will be submitted for local permissions.Informed consent to participate will be obtained from all participants. The participant has the right to refuse participation without giving a reason. After the participant has entered, the clinician remains free to give alternative treatment to that specified in the protocol at any stage if they feel it to be in the best interest of the participant.
: Not applicable as study protocol.
: The authors declare that they have no competing interests.